AQR Capital Management
AXSM icon

AQR Capital Management’s Axsome Therapeutics AXSM Stock Holding History

AQR Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.9M Buy
114,025
+9,966
+10% +$2.16M 0.01% 1046
2026
Q1 		$17.6M Buy
104,059
+641
+0.6% +$111K 0.01% 1080
2025
Q4 		$18.9M Sell
103,418
-15,238
-13% -$2.13M 0.01% 958
2025
Q3 		$14.4M Sell
118,656
-9,161
-7% -$1.03M 0.01% 947
2025
Q2 		$13.3M Buy
127,817
+69,454
+119% +$7.35M 0.01% 887
2025
Q1 		$6.81M Buy
58,363
+20,152
+53% +$2.3M 0.01% 1006
2024
Q4 		$3.23M Buy
38,211
+11,049
+41% +$1.02M ﹤0.01% 1282
2024
Q3 		$2.44M Buy
27,162
+14,326
+112% +$1.25M ﹤0.01% 1402
2024
Q2 		$1.03M Sell
12,836
-15,440
-55% -$1.14M ﹤0.01% 1736
2024
Q1 		$2.26M Buy
28,276
+19,946
+239% +$1.67M ﹤0.01% 1361
2023
Q4 		$663K Sell
8,330
-1,431
-15% -$95.7K ﹤0.01% 1758
2023
Q3 		$682K Sell
9,761
-1,946
-17% -$145K ﹤0.01% 1743
2023
Q2 		$841K Buy
11,707
+2,882
+33% +$213K ﹤0.01% 1626
2023
Q1 		$544K Buy
8,825
+148
+2% +$9.72K ﹤0.01% 1750
2022
Q4 		$669K Sell
8,677
-3,108
-26% -$186K ﹤0.01% 1712
2022
Q3 		$526K Buy
11,785
+6,089
+107% +$304K ﹤0.01% 1761
2022
Q2 		$218K Buy
+5,696
New +$180K ﹤0.01% 1972
2021
Q1 		– Sell
-6,774
Closed -$552K – 2193
2020
Q4 		$552K Sell
6,774
-7,231
-52% -$541K ﹤0.01% 1742
2020
Q3 		$998K Sell
14,005
-3,750
-21% -$292K ﹤0.01% 1409
2020
Q2 		$1.46M Sell
17,755
-3,630
-17% -$279K ﹤0.01% 1304
2020
Q1 		$1.26M Sell
21,385
-6,480
-23% -$528K ﹤0.01% 1247
2019
Q4 		$2.88M Buy
27,865
+8,277
+42% +$334K ﹤0.01% 1129
2019
Q3 		$396K Buy
+19,588
New +$503K ﹤0.01% 1832

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

AQR Capital Management's AXSM Position: Q2 2026 in Review

AQR Capital Management increased its Axsome Therapeutics (AXSM) stake by 9.6% in Q2 2026, buying an estimated $2.16M and bringing the position to 114,025 shares worth $27.9M. The position accounts for 0.01% of the portfolio, ranked #1046.

AQR Capital Management first reported a position in AXSM in Q3 2019 and has held it in 23 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • AQR Capital Management held 114,025 shares of Axsome Therapeutics worth $27.9M as of Q2 2026.
  • AQR Capital Management bought 9,966 Axsome Therapeutics shares in Q2 2026, an estimated $2.16M.
  • Axsome Therapeutics made up 0.01% of AQR Capital Management's portfolio in Q2 2026, its #1046 holding.
  • AQR Capital Management first reported a position in Axsome Therapeutics in Q3 2019 and has held it in 23 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.